Cerebrovascular Reactivity Testing with HD-DOT in Sickle Cell Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses HD-DOT alongside MRI-based measures to examine cerebrovascular reactivity and oxygen extraction in participants with and without altered cerebral oxygen delivery. Oxygen extraction fraction will be measured with MRI, while CVR will be assessed using a controlled carbon dioxide challenge delivered safely with the RespirACT device. The goal is to identify imaging biomarkers of brain tissue under metabolic stress and relate these biomarkers to clinical and radiologic outcomes. By applying HD-DOT, the study aims to characterize regional OEF and CVR trajectories over time and across participants. The trial is conducted at Washington University in St. Louis with no listed collaborators.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 6-70 Years Old
* Able to participate in MRI scan without sedation
* May or may not have HbSS or beta thalassemia null genotypes of sickle cell anemia

Exclusion Criteria:

* Significant craniofacial malformation or technical contraindications to DOT monitoring (for HDDOT imaging)
* Metal in/on the body that is contraindicated for MRI safety (for MRI imaging)

Where it's running

• Washington University in St. Louis
  St Louis, Missouri, United States Recruiting

Study contacts

• Study coordinator: Kristin Guilliams, MD
• Email: kristinguilliams@wustl.edu
• Phone: 3144545436

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding brain blood flow and metabolism in children

  This study is trying to see how blood flow and metabolism in the brain affect development in children, especially those with sickle cell disease and stroke, by using advanced MRI techniques.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT04157179

• Adapting and testing PEN-Plus in Zambian primary care

  Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.

  Recruiting Centre for Infectious Disease Research in Zambia · Lusaka, Lusaka Province · NCT07753681

• Newborn Sickle Cell Screening in Mozambique

  We’re testing a three-part plan to help babies in Mozambique get diagnosed early for sickle cell disease and start care quickly.

  Recruiting St. Jude Children's Research Hospital · Nhamatanda, Sofala · NCT07719972

• Optimizing Hydroxyurea in Children with Sickle Cell in Africa

  This study tests whether raising hydroxyurea to a maximum tolerated dose is safe and beneficial for Ugandan children with sickle cell anemia already taking a fixed daily dose.

  Recruiting Phase 1/2 Children's Hospital Medical Center, Cincinnati · Kampala · NCT07708714

• Hematopoietic stem cell editing to treat sickle cell disease

  This study tests whether a patient’s own blood stem cells can be edited to remove the sickle cell triggering gene and then returned to the patient.

  Recruiting Phase 1 Boston Children's Hospital · Boston, Massachusetts · NCT07708350

• Virtual reality options to help with VOC pain in adults with SCD

  This study tests whether headset-based virtual reality can help reduce pain for adults with sickle cell disease during vaso-occlusive crises treated in an infusion center.

  Recruiting University of Maryland, Baltimore · Baltimore, Maryland · NCT07674277

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.